Back to top
more

ContextLogic Inc. (LOGC)

(Real Time Quote from BATS)

$6.25 USD

6.25
141,720

+0.06 (0.97%)

Updated Nov 6, 2024 03:14 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 26% (66 out of 251)

Industry: Internet - Commerce

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Brokerage Reports

Research for LOGC

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

[LOGC]

Reports for Purchase

Showing records 1 - 20 ( 50 total )

Industry: Medical - Biomedical and Genetics

Record: 1

02/16/2022

Company Report

Pages: 3

Termination of Coverage

Provider: H.C. Wainwright & Co., Inc.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 2

12/22/2021

Company Report

Pages: 4

SUNRISE Interim Data Expected in 2Q 2022; Next Drug Candidate LB-401 Selected For HT1

Provider: H.C. Wainwright & Co., Inc.

Analyst: ZHANG E

Price: 5.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 3

11/19/2021

Company Report

Pages: 5

Key Interim Data of SUNRISE Trial Coming Soon in December; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ZHANG E

Price: 5.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 4

10/18/2021

Daily Note

Pages: 4

Positive Albumin-2a Data Highly Encouraging; Interim Data at YE a Key Catalyst; Reiterate Buy.

Provider: H.C. Wainwright & Co., Inc.

Analyst: ZHANG E

Price: 5.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 5

09/28/2021

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for LOGC

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 6

08/10/2021

Company Report

Pages: 4

Expecting SUNRISE Interim Data at YE21; Reiterate Buy and $15 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: ZHANG E

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 7

06/07/2021

Company Report

Pages: 46

Take a GeneRide at SunRise; Initiate with a Buy and $15 TP

Provider: H.C. Wainwright & Co., Inc.

Analyst: ZHANG E

Price: 100.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 8

06/23/2020

Company Report

Pages: 4

Dropping Coverage

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 9

06/10/2020

Industry Report

Pages: 7

Healthcare - Dial In On Jun. 16 For Real-Life Insights into MMA from the Patient Perspective

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 10

05/15/2020

Company Report

Pages: 9

GeneRide Leaves No Stone Unturned - ASGCT Takeaways Part 2

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 11

05/15/2020

Daily Note

Pages: 4

MID-DAY SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 12

05/13/2020

Daily Note

Pages: 4

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 13

05/13/2020

Company Report

Pages: 8

GeneRide Leaves No Stone Unturned - ASGCT Takeaways

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 14

05/12/2020

Daily Note

Pages: 5

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 15

05/12/2020

Company Report

Pages: 8

1Q20 - Still in the Full Swing of Things Despite COVID-19

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 16

03/20/2020

Industry Report

Pages: 9

Yas'' Weekly Recap of Our Key Notes and 16 Doc Calls Upcoming in 1H20

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 17

03/17/2020

Daily Note

Pages: 4

MID-DAY SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 18

03/17/2020

Company Report

Pages: 7

4Q19 - The Skies Are Clearing for LB-001

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 19

02/14/2020

Industry Report

Pages: 7

Yas'' Weekly Recap of Our Key Notes and 10 Doc Calls Upcoming in 1H20

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 20

02/11/2020

Daily Note

Pages: 4

Don''t Lose Sight of the Prize

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 10.00

Research Provided by a Third Party
// eof